Corporate news | The Columbian-Progress

Home

AP
premium content - for subscribers only
Click to subscribe

Editorial Roundup: United States
By THE ASSOCIATED PRESS
Wed,12/07/22-6:09AM , 342 Reads
Excerpts from recent editorials in the United States and abroad:

Dec. 5

The Washington Post on microchips, the U.S. and the future
Click Here to Read More

AP
premium content - for subscribers only
Click to subscribe

Mississippi grain company's ex-CEO indicted on fraud charges
By THE ASSOCIATED PRESS
Tue,12/06/22-5:55PM , 517 Reads
GREENVILLE, Miss. (AP) — The former leader of a Mississippi grain storage and processing company has been indicted on federal and state charges, more than a year after the company filed for bankruptcy, prosecutors said Tuesday.

John R. Coleman, 46, of Greenwood, Mississippi, is the former CEO of Express Grain Terminals, LLC.
Click Here to Read More

AP
free content

Closing prices for crude oil, gold and other commodities
By THE ASSOCIATED PRESS
Tue,12/06/22-2:13PM , 337 Reads
Benchmark U.S. crude oil for January delivery fell $2.68 to $74.25 a barrel Tuesday. Brent crude for February delivery fell $3.33 to $79.35 a barrel.
Click Here to Read More

A sign in front of the Food and Drug Administration building is seen on Dec. 10, 2020, in Silver Spring, Md. Expedited drug approvals slowed in 2022, as the FDA's controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency’s own leaders. With less than a month remaining in the year, the agency’s drug center has granted 10 accelerated approvals — fewer than the tally in each of the last five years, when use of the program reached all-time highs. (AP Photo/Manuel Balce Ceneta, File)

AP
registered content - login required to view
Click to register / login

Speedier drug approvals hit slowdown as FDA faces scrutiny
By MATTHEW PERRONE - AP Health Writer
Tue,12/06/22-1:53PM , 238 Reads
WASHINGTON (AP) — Expedited drug approvals slowed this year as the Food and Drug Administration's controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency’s own leaders.
Click Here to Read More

Subscribe to Corporate news